本帖最后由 老马 于 2013-3-13 13:43 编辑 % B; d& ?( r, V ^" w3 w& a
" X% B' w2 \$ N( ]健择（吉西他滨）+顺铂+阿瓦斯汀; C1 |" C5 s0 W. Q& ]( D
Gemzar +Cisplatin + Avastin+ P( o4 h; ?* f+ ?6 e2 t
http://annonc.oxfordjournals.org/content/21/9/1804.full
/ ^* T0 ]' |' vOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
/ l8 k& i' H, A* \Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ; C4 B |& ~) G3 V/ x% J& b
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. + c& ]8 v) ^% i0 r
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 327)
% F8 f' O6 Y. n' Q华为网盘附件：* G1 P" G1 `$ e) ~6 z. G1 d
【华为网盘】ava.JPG+ _; C, Q8 f- J
|
显身卡
